Search clinical trials for: Angiotensin II Infusion

Total 12842 results

Roxane Laboratories

Completed

Crossover Bioequivalence Study of Irbesartan 300 mg Tablets Under Fed Conditions

Hypertension

United States
Ain Shams University

Completed

Chronopharmacology of Valsartan in Normotensive Subjects

Healthy Normotensive Volunteers

Egypt
Jiangsu HengRui Medicine Co., Ltd.

Completed

The Drug-drug Interaction of SP2086 and Valsartan

Type 2 Diabetes

China
Bristol-Myers Squibb
Sanofi

Completed

Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve)

Congestive Heart Failure

Netherlands, Portugal, Spain, United States, Belgium, Italy, Argentina, Brazil, Canada, France, Germany, Mexico, South Africa, Sweden, Australia, Russian Federation, Poland, Czech Republic, Denmark, Ireland, Hungary, Switzerland, Gr... and more
Karin Skov
AstraZeneca; University of Aarhus

Unknown

Danish Hypertension Prevention Project - DHYPP

Hypertension

Denmark
Fundación Cardiovascular de Colombia
AstraZeneca

Terminated

Clinical Trial to Assess the Effects of Candesartan on the Carbohydrate Metabolism of Obese Subjects (ARAMIA)

Obesity | Glucose Intolerance

Colombia
Seung-Jung Park
Novartis

Completed

Valsartan for Suppression of Plaque Volume and Restenosis After Drug-Eluting Stent (VAL-SUPPRES)

Coronary Artery Disease

Korea, Republic of
Osaka City University

Completed

Prevention of CHOP-induced Chronic Cardiotoxicity

Non-Hodgkin's Lymphoma

Japan
Sanofi
Bristol-Myers Squibb

Completed

The Efficacy and Safety of Irbesartan 150/12.5 mg and 300/25 mg in Patients With Mild Hypertension

Hypertension

United States
Steno Diabetes Center Copenhagen

Completed

Optimal Dose of Irbesartan for Renoprotection in Type 2 Diabetic Patients With Persistent Microalbuminuria

Type 2 Diabetes | Microalbuminuria

Denmark
Rambam Health Care Campus

Unknown

Non-Insulin Dependent Diabetes Mellitus (NIDDM) and Angiotensin Converting Enzyme 2 (ACE2): Diabetic Patients Treated With Antihypertensive Drugs

NIDDM

Israel
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension

Essential Hypertension

China
The Affiliated Hospital of Qingdao University

Recruiting

A Bioequivalence Trial of Irbesartan Tablets（0.15g） in Healthy Chinese Subjects

Bioequivalence | Irbesartan Tablets (0.15g/Tablet) | Under Fasted Condition | Under Fed Condition

China
Samsung Medical Center

Recruiting

Strain vs. Left Ventricular Ejection Fraction-based Cardiotoxicity Prevention in Breast Cancer

Breast Cancer | Cardiotoxicity | Prevention | Adjuvant | Trastuzumab

Korea, Republic of
Mayo Clinic
National Heart, Lung, and Blood Institute (NHLBI)

Completed

CR Aim #2 - AT1 Receptor Blockade & ACE Inhibition Effect on Humoral Function

Cardiorenal Syndrome (CRS)

United States
Takeda

Completed

Azilsaltan Tablets (Azilva Tablets) Special Drug Use Surveillance "Hypertension Complicated by Diabetes "

Hypertension

Japan
Boehringer Ingelheim

Completed

J-TARGET,Japanese Telmisartan Study for Antihypertensive Good Effect in Long Term Observation

Hypertension
Ranbaxy Laboratories Limited

Completed

Bioequivalence Study of Valsartan 320mg Tablets Under Fasting Conditions

Healthy

India
Boehringer Ingelheim

Completed

Safety, Tolerability and Efficacy of Micardis® in Patients With Essential Hypertension

Hypertension
AstraZeneca
Takeda

Completed

DIabetic Retinopathy Candesartan Trials (DIRECT)

Type 2 Diabetes
National Taiwan University Hospital
Daiichi Sankyo Taiwan Ltd.

Completed

Evaluation of Effects of Exercise Training and ARB in DM Patients

Exercise Training | Vascular Function

Taiwan
Novartis

Completed

Effect of Valsartan on Proteinuria in Patients With Hypertension and Diabetes Mellitus

Hypertension | Type 2 Diabetes | PROTEINURIA
Novartis

Completed

Efficacy and Safety of Fluvastatin or Valsartan and Their Combination in Dyslipidemic Patients With Hypertension and Endothelial Dysfunction

Hypertension | Dyslipidemia

Russian Federation
Novartis

Completed

8 Weeks Study to Evaluate the Efficacy and Safety of Valsartan in Combination With Aliskiren Compared to Valsartan Alone in Patients With Stage 2 Hypertension (VANTAGE)

Stage 2 Hypertension

United States
AstraZeneca

Completed

Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Added)

Congestive Heart Failure
Gruppo di Ricerca GISSI

Completed

GISSI-AF - Use of Valsartan an Angiotensin II AT1-Receptor Blocker in the Prevention of Atrial Fibrillation Recurrence

Atrial Fibrillation

Italy, Switzerland
Novartis Pharmaceuticals

Terminated

A Study in Patients With Diabetes Mellitus Type II of the Effect on Albuminuria of 24 Week Treatment With Valsartan, Benazepril, and Valsartan+Benazepril

Hypertension | Diabetic Nephropathy

Switzerland
Technische Universität Dresden

Completed

Characterization of Vascular Effects of Angiotensin II in Dorsal Human Hand Veins.

Healthy Subjects

Germany
Hackensack Meridian Health

Terminated

Study of TelmisartanFor the Prevention of Acute GVHD Post Allogeneic Hematopoietic Stem Cell Transplantation

GVHD

United States
The University of Texas Health Science Center,...

Withdrawn

Candesartan as an Adjunctive Treatment for Bipolar Depression

Bipolar Disorder Depression

United States
Novartis Pharmaceuticals

Completed

Pharmacokinetics Following Single-dose of Valsartan in Japanese Pediatric Patients

Hypertension | Chronic Kidney Disease | Nephrotic Syndrome

Japan
Stanford University

Terminated

Treatment of Insulin Resistance in Hypertensive, Obese Adolescents

Hypertension | Insulin Resistance | Dyslipidemia

United States
Augusta University

Unknown

Effectiveness of Avapro in Obese Normotensive/Hypertensive African Americans (Avapro3)

Hypertension | Obesity | Stress, Psychological | Blood Pressure

United States
Takeda

Completed

A Phase 1 Food Effect Study of Azilsartan (TAK-536) Pediatric Formulation

Healthy Volunteers

Japan
Takeda

Completed

A Phase 1, Bio-equivalence Study of TAK-536 Pediatric Formulation

Japanese Healthy Adult Male Participants

Japan
Takeda

Withdrawn

A Study to Evaluate the Effects of Azilsartan on Coronary Artery Plaque in Essential Hypertensive Patients With Stable Angina and Dyslipidemia. (ALIVE)

Essential Hypertension With Stable Angina and Dyslipidemia

Japan
Takeda

Completed

A Phase 3 Pharmacokinetic Study of TAK-536 (Azilsartan) in Pediatric Patients 6 to Less Than 16 Years With Hypertension

Pediatric Hypertension

Japan
Boehringer Ingelheim

Terminated

SAFE-CRP: Structural Alterations and Function of Endothelium in Cardiovascular Risk Patients

Hypertension | Coronary Arteriosclerosis

Germany
Novartis

Completed

A Study Of Valsartan Used To Treat Hypertension For Up To 56 Weeks In Children Ages 1 - 5 Years Who Have Hypertension

Hypertension

United States
AstraZeneca

Completed

Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Preserved)

Congestive Heart Failure
Ludwig-Maximilians - University of Munich
Bayer

Completed

Regulation of Inflammatory Parameters by Telmisartan in Hypertensive Patients (METATEL)

Hypertension | Metabolic Syndrome | Hypertriglyceridemia

Germany
Charite University, Berlin, Germany
Bristol-Myers Squibb

Completed

Effect of Irbesartan on Insulin Sensitivity in Chronic Heart Failure

Chronic Heart Failure

Germany
Novartis

Completed

Bioavailability of Aliskiren and Valsartan as a Single Tablet vs. the Same Doses of the Two Drugs Given Separately to Healthy Subjects.

Healthy

United States
Steno Diabetes Center Copenhagen
Bristol-Myers Squibb; Sanofi-Synthelabo

Completed

Irbesartan in Type 2 Diabetes

Hypertension | Type 2 Diabetes | Microalbuminuria
Norwegian University of Science and Technology
St. Olavs Hospital; Alesund Hospital; Namsos Hospital; Volvat Medisinsk Senter...

Recruiting

Bariatric Surgery and Pharmacokinetics of Irbesartan

Obesity, Morbid

Norway
Takeda

Completed

Azilsartan Tablets Special Drug Use Surveillance: Long-term Use

Hypertension

Japan
Novartis

Completed

A Study Of Valsartan Used To Treat Hypertension For Up To 13 Months In Hypertensive Children Ages 6 - 16 Years Of Age

Hypertension

Germany, United States
Boehringer Ingelheim

Completed

Post-marketing Study to Supplement Data on Safety, Tolerability and Efficacy of Micardis® With Special Emphasis on the Control of Blood Pressure

Hypertension
Boehringer Ingelheim

Completed

Post-Marketing Surveillance of Micardis® (Telmisartan) in Patients With Hypertension

Hypertension
Boehringer Ingelheim

Completed

Pharmacovigilance and Patient Compliance in Hypertensive Patients

Hypertension

3

Subscribe